• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press

FDA Confirms Tirzepatide Shortage is Over

  • December 25, 2024
  • Pharma & Biotech
FDA announces end of tirzepatide shortage, ensuring stable supply of this GLP-1 medication for diabetes and obesity treatment. Patients now have reliable access.
Continue Reading

Key Cybersecurity Market Opportunities in 2025

  • December 24, 2024
  • Tech
Discover key cybersecurity market opportunities in 2025, including AI, Zero Trust, and blockchain, to combat threats like ransomware and IoT vulnerabilities.
Continue Reading

Top 10 Emerging Tech Markets in 2024

  • December 23, 2024
  • Tech
Discover the top 10 emerging tech markets in 2024, including AI, quantum computing, and 5G, and their transformative impact on industries.
Continue Reading

Emerging Trends in FDA Approvals for Rare Metabolic Disorders

  • December 20, 2024
  • Pharma & Biotech
FDA approves Ionis’ treatment for a rare metabolic disorder, highlighting trends in rare disease drug approvals and their impact on patient care.
Continue Reading

US Drug Spending Hits $450B: Impact on Healthcare Costs

  • December 19, 2024
  • Pharma & Biotech
US spent $450B on drugs last year, driving up healthcare costs and impacting patient care and hospital budgets. Explore the economic implications.
Continue Reading

Leading HealthTech VC Firms to Watch in 2024

  • December 19, 2024
  • Pharma & Biotech, Tech
Discover top venture capital firms in HealthTech for 2024, driving innovation and growth in healthcare technology.
Continue Reading

Nvidia and Broadcom Battle in the AI Chip Arena

  • December 18, 2024
  • Tech
Nvidia and Broadcom vie for dominance in the AI chip market, shaping the future of AI with GPUs and custom solutions for hyperscalers.
Continue Reading

Nimble Therapeutics Joins AbbVie in $200M Deal

  • December 17, 2024
  • Pharma & Biotech
AbbVie makes another small I&I acquisition, buying Nimble for $200M to enhance its immunology pipeline with innovative oral peptide therapies.
Continue Reading

European Central Bank Lowers Rates

  • December 16, 2024
  • Pharma & Biotech, Tech
The European Central Bank lowers rates to tackle inflation and boost economic recovery, impacting borrowing costs and consumer spending in the Eurozone.
Continue Reading

Step-by-Step Competitive Analysis for Tech Startups

  • December 13, 2024
  • Pharma & Biotech, Tech
Learn how to perform competitive analysis for tech startups to gain insights, identify opportunities, and stay ahead in the competitive tech landscape.
Continue Reading

Posts pagination

Previous 1 … 29 30 31 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.